Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo ...

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

Artificial intelligence is reshaping drug discovery, but its integration raises critical questions: How do we balance AI-driven insights with data integrity, human expertise, and ethical ...

2025 has been a whirlwind year thus far for the life sciences industry as the sector continues to grapple with a diverse set of evolving challenges. The simultaneous impacts of global trade shifts, ...

A global diagnostics and contract manufacturing company faced the challenge of harmonizing quality processes across its enterprise while minimizing costs and complexity. Rather than migrating data ...

Novartis is making a major investment in North Carolina’s Research Triangle, committing $771 million across three projects that will strengthen U.S. pharmaceutical manufacturing. The expansion ...

In the July issue of Life Science Leader, Cliff Mintz wrote a global update on follow-on biologics in unregulated markets, the European Union, and the United States. With intense public debate around ...

Q3 2025 delivered meaningful momentum across the gene, cell, and RNA therapy landscape, highlighted by four global approvals. China’s NMPA cleared Hrain Biotechnology’s Hicara CAR-T for large B-cell ...

In high-throughput biotech and pharmaceutical environments, achieving agility and precision is crucial, especially in functions like Environmental Monitoring (EM) and Sample Management. When these ...

On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during ...

Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

Lab testing services are critical to pharmaceutical and biopharmaceutical product development, and those companies often choose to outsource to CROs/CDMOs via a fee-for-service model or by dedicating ...